Literature DB >> 7891116

A cellular stress model for the sequestration of redox-active glial iron in the aging and degenerating nervous system.

X Wang1, F Manganaro, H M Schipper.   

Abstract

The mechanisms responsible for the accumulation of redox-active brain iron in normal senescence and in Parkinson's disease remain poorly understood. The aminothiol compound cysteamine (CSH) induces the appearance of autofluorescent, iron-rich cytoplasmic granules in cultured astroglia that are identical to glial inclusions that progressively accumulate in the aging periventricular brain. Both in situ and in culture, these glial inclusions appear to arise in the context of a generalized cellular stress (heat shock) response. Several laboratories have previously concluded that porphyrins and heme ferrous iron are responsible, respectively, for redorange autofluorescence and nonenzymatic peroxidase activity in the glial inclusions. In the present study we found that, contrary to hypothesis, CSH suppresses the incorporation of the heme precursors delta-amino[14C]-levulinic acid and [14C]glycine into astroglial porphyrin and heme in primary culture. Similar results were obtained when the cells were preloaded with radiolabeled heme precursors for 24 h before CSH treatment, suggesting that the latter directly inhibits porphyrin-heme biosynthesis rather than limiting precursor uptake by these cells. We also demonstrated that CSH exposure results in the sequestration of iron-59 by astroglial mitochondria (granule precursors). The results of this study suggest that stress-related trapping of nonheme iron by astroglial mitochondria may be an important mechanism underlying the pathological accumulation of redox-active iron in the basal ganglia of subjects with Parkinson's disease. CSH-treated astrocytes provide a useful model to investigate the role of stress-related dysregulation of neuroglial iron metabolism in the aging and degenerating nervous system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7891116     DOI: 10.1046/j.1471-4159.1995.64041868.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population.

Authors:  Mario Ezquerra; Jaume Campdelacreu; Esteban Muñoz; Eduard Tolosa
Journal:  J Neurol       Date:  2005-08-01       Impact factor: 4.849

2.  Delayed ALK5 inhibition improves functional recovery in neonatal brain injury.

Authors:  Mariano Guardia Clausi; Steven W Levison
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

Review 3.  Heme oxygenase-1 in Alzheimer disease: a tribute to Moussa Youdim.

Authors:  Hyman M Schipper
Journal:  J Neural Transm (Vienna)       Date:  2010-06-20       Impact factor: 3.575

4.  GLUT2 immunoreactivity in Gomori-positive astrocytes of the hypothalamus.

Authors:  John K Young; James C McKenzie
Journal:  J Histochem Cytochem       Date:  2004-11       Impact factor: 2.479

5.  Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases.

Authors:  H M Schipper
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

6.  Role of iron in the pathogenesis of cysteamine-induced duodenal ulceration in rats.

Authors:  Tetyana Khomenko; Sandor Szabo; Xiaoming Deng; Hideki Ishikawa; Gregory J Anderson; Gordon D McLaren
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-02       Impact factor: 4.052

7.  Spatial monitoring of toxicity in HMOX-LacZ transgenic mice.

Authors:  Rachel Young; C Roland Wolf; Ken Brown; John D Hayes; C Bruce A Whitelaw
Journal:  Transgenic Res       Date:  2010-01-14       Impact factor: 2.788

Review 8.  Association of transferrin G258A and transferrin receptor A82G polymorphisms with the risk of Parkinson disease in certain area.

Authors:  Yan Wang; Yong Wang; Minhua Zhou; Deqi Jiang; Xun Deng
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.